LUNG CANCER IN 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets

    loading  Checking for direct PDF access through Ovid

Abstract

Lung-cancer treatment paradigms continue to advance as we exploit our growing understanding of the genetic basis of both tumorigenesis and therapy resistance. Moreover, ongoing developments with targeted therapies are improving patient outcomes, with two new drugs approved in 2015 for non-small-cell lung cancer and many others showing promise.

Related Topics

    loading  Loading Related Articles